ENDOCAN-1
Research type
Research Study
Full title
ENDOCAN-1: A feasibility randomised controlled trial of the efficacy of a cannabinoid oral solution in the management of endometriosis-associated pain
IRAS ID
1010848
Contact name
Lucy Whitaker
Contact email
Sponsor organisation
University of Edinburgh
ISRCTN Number
ISRCTN13210908
Research summary
This study, funded by the Chief Scientist Office (CSO) will use a solution called MRX-1 which is a cannabinoid solution that does not contain THC which we will use to see if it reduces pain in patients with endometriosis. Endometriosis is a condition that affects 1 in 10 women or those assigned female at birth and causes pain, infertility and can reduce quality of life. At the moment available drug treatments have unacceptable side effects and are often hormonal and are contraceptive. There is an unmet need to find new treatments. Cannabinoids have been shown to be effective in other pain conditions. We will recruit 100 women over a period of 18 months from NHS Lothian and NHS Grampian. Once eligibility has been confirmed the participant will be selected by chance (randomised) to have either the trial solution or placebo solution. The solution will be dosed according to the participants BMI and the dose can be increased weekly up to a maximum of 6.25mg/kg twice daily. They will take the solution for a 12 week period. We will collect questionnaires to assess pain scores and quality of life information. In NHS Lothian, we will ask participants if they are willing to wear a smartwatch to collect data on activity, sleep, ambient light and temperature. This would be optional. This study will help us develop a larger multi-centre study.
REC name
London - South East Research Ethics Committee
REC reference
26/LO/0150
Date of REC Opinion
20 Feb 2026
REC opinion
Favourable Opinion